Skip to main content
Erschienen in: Journal of Radiation Oncology 3/2019

25.10.2019 | Original Research

Definitive chemoradiation followed by stereotactic body radiotherapy boost for inoperable endometrial cancer

verfasst von: Shraddha M. Dalwadi, Constantine Mantz, Bui Tung, Nabila Waheed, Danny Tran, Mark Bonnen, Michelle Ludwig

Erschienen in: Journal of Radiation Oncology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Objectives

For inoperable endometrial cancer (ECA) patients, definitive chemoradiation with stereotactic body radiotherapy (SBRT) boost may be an option. SBRT schedules and dose distributions approximate brachytherapy boost (BB) radiobiologic dosing, while eliminating the need for applicator placement and thus anesthesia. We report toxicity, disease control, and quality-of-life outcomes of a multi-institutional series of SBRT for ECA.

Methods

Twenty-three patients met the following eligibility criteria: (1) primary ECA, (2) contraindication or refusal of BB, and (3) need for definitive radiation (RT). Prior to SBRT, patients received pelvic RT +/− nodal boost concurrent with cisplatin. SBRT dose of 25.0–35.0 Gy was prescribed to a high-risk clinical target volume (HR-CTV) in 4–5 fractions. Assessments included (1) post-treatment disease surveillance, (2) toxicity using the U.S. National Cancer Institute’s CTCAE scales, and (3) quality-of-life using FACT-G.

Results

Median follow-up was 31 months. BB was infeasible due to medical comorbidities, patient refusal, and technical contraindications (73.9%, 21.7%, and 4.3%, respectively). Most patients were FIGO stage I (60.8%). Mean cumulative dose to high-risk clinical target volume (HR-CTV) was 88.94 Gy (range 75.50–93.83 Gy). Mean SBRT dose to 95% of the planning target volume (PTV) was 32.55 Gy (range 25.00–35.77 Gy), and mean PTV receiving 100% of the dose was 95.29% (range 91.48–99.01%). No patients had grade 2+ long-term gastrointestinal or genitourinary toxicity. Locoregional and distant control was 91.6% at 1 year and 85.4% at 2 year. Only one patient died due to ECA at 6 months. Overall survival was 95.0% at 1 year, 74.0% at 2 year, and 59.2% at 5 year. Patient-reported physical and emotional well-being worsened but improved after the acute phase of treatment. Functional and social/family well-being worsened after 1 month.

Conclusion

Definitive chemoradiation with SBRT boost is safe and effective alternative when BB is not possible.
Literatur
2.
Zurück zum Zitat Koh W-J et al (2018) Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 16(2):170–199CrossRef Koh W-J et al (2018) Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 16(2):170–199CrossRef
3.
Zurück zum Zitat Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, Negri E, Franceschi S, la Vecchia C (2010) Metabolic syndrome and endometrial cancer risk. Ann Oncol 22(4):884–889CrossRef Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, Negri E, Franceschi S, la Vecchia C (2010) Metabolic syndrome and endometrial cancer risk. Ann Oncol 22(4):884–889CrossRef
4.
Zurück zum Zitat Kim JJ, Kurita T, Bulun SE (2013) Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev 34(1):130–162CrossRef Kim JJ, Kurita T, Bulun SE (2013) Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev 34(1):130–162CrossRef
5.
Zurück zum Zitat MacMahon B (1974) Risk factors for endometrial cancer. Gynecol Oncol 2(2):122–129CrossRef MacMahon B (1974) Risk factors for endometrial cancer. Gynecol Oncol 2(2):122–129CrossRef
6.
Zurück zum Zitat Fishman DA et al (1996) Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma of the endometrium. Gynecol Oncol 61(2):189–196CrossRef Fishman DA et al (1996) Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma of the endometrium. Gynecol Oncol 61(2):189–196CrossRef
7.
Zurück zum Zitat Varia M et al (1987) Primary radiation therapy for medically inoperable patients with endometrial carcinoma-stages I–II. Int J Radiat Oncol Biol Phys 13(1):11–15CrossRef Varia M et al (1987) Primary radiation therapy for medically inoperable patients with endometrial carcinoma-stages I–II. Int J Radiat Oncol Biol Phys 13(1):11–15CrossRef
8.
Zurück zum Zitat Kucera H et al (1998) Treatment of endometrial carcinoma with high-dose-rate brachytherapy alone in medically inoperable stage I patients. Acta Obstet Gynecol Scand 77(10):1008–1012CrossRef Kucera H et al (1998) Treatment of endometrial carcinoma with high-dose-rate brachytherapy alone in medically inoperable stage I patients. Acta Obstet Gynecol Scand 77(10):1008–1012CrossRef
9.
Zurück zum Zitat Nag S et al (2000) The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 48(3):779–790CrossRef Nag S et al (2000) The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 48(3):779–790CrossRef
10.
Zurück zum Zitat Potters L et al (2010) American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 76(2):326–332CrossRef Potters L et al (2010) American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 76(2):326–332CrossRef
11.
Zurück zum Zitat Jones R et al (2014) Dosimetric feasibility of stereotactic body radiation therapy as an alternative to brachytherapy for definitive treatment of medically inoperable early stage endometrial cancer. Radiat Oncol 9(1):164CrossRef Jones R et al (2014) Dosimetric feasibility of stereotactic body radiation therapy as an alternative to brachytherapy for definitive treatment of medically inoperable early stage endometrial cancer. Radiat Oncol 9(1):164CrossRef
12.
Zurück zum Zitat Kemmerer E et al (2013) Use of image-guided stereotactic body radiation therapy in lieu of intracavitary brachytherapy for the treatment of inoperable endometrial neoplasia. Int J Radiat Oncol Biol Phys 85(1):129–135CrossRef Kemmerer E et al (2013) Use of image-guided stereotactic body radiation therapy in lieu of intracavitary brachytherapy for the treatment of inoperable endometrial neoplasia. Int J Radiat Oncol Biol Phys 85(1):129–135CrossRef
13.
Zurück zum Zitat Demiral S, Beyzadeoglu M, Uysal B, Oysul K, Kahya YE, Sager O, Dincoglan F, Gamsiz H, Dirican B, Surenkok S (2013) Evaluation of stereotactic body radiotherapy (SBRT) boost in the management of endometrial cancer. Neoplasma 60(3):322–327CrossRef Demiral S, Beyzadeoglu M, Uysal B, Oysul K, Kahya YE, Sager O, Dincoglan F, Gamsiz H, Dirican B, Surenkok S (2013) Evaluation of stereotactic body radiotherapy (SBRT) boost in the management of endometrial cancer. Neoplasma 60(3):322–327CrossRef
14.
Zurück zum Zitat Higginson DS et al (2011) Stereotactic body radiotherapy (SBRT): technological innovation and application in gynecologic oncology. Gynecol Oncol 120(3):404–412CrossRef Higginson DS et al (2011) Stereotactic body radiotherapy (SBRT): technological innovation and application in gynecologic oncology. Gynecol Oncol 120(3):404–412CrossRef
15.
Zurück zum Zitat Cengiz M et al (2012) Comparison of intracavitary brachytherapy and stereotactic body radiotherapy dose distribution for cervical cancer. Brachytherapy 11(2):125–129CrossRef Cengiz M et al (2012) Comparison of intracavitary brachytherapy and stereotactic body radiotherapy dose distribution for cervical cancer. Brachytherapy 11(2):125–129CrossRef
16.
Zurück zum Zitat Spratt DE et al (2013) A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer. Brachytherapy 12(5):428–433CrossRef Spratt DE et al (2013) A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer. Brachytherapy 12(5):428–433CrossRef
17.
Zurück zum Zitat Jabbari S et al (2012) Stereotactic body radiotherapy as monotherapy or post–external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 82(1):228–234CrossRef Jabbari S et al (2012) Stereotactic body radiotherapy as monotherapy or post–external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 82(1):228–234CrossRef
18.
Zurück zum Zitat Katz A, Kang J (2014) Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. Radiat Oncol 9(1):1CrossRef Katz A, Kang J (2014) Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. Radiat Oncol 9(1):1CrossRef
19.
Zurück zum Zitat Nag S, Gupta N (2000) A simple method of obtaining equivalent doses for use in HDR brachytherapy. Int J Radiat Oncol Biol Phys 46(2):507–513CrossRef Nag S, Gupta N (2000) A simple method of obtaining equivalent doses for use in HDR brachytherapy. Int J Radiat Oncol Biol Phys 46(2):507–513CrossRef
20.
Zurück zum Zitat Haas JA, Witten MR, Clancey O, Episcopia K, Accordino D, Chalas E (2012) CyberKnife boost for patients with cervical cancer unable to undergo brachytherapy. Front Oncol 2, article 25 Haas JA, Witten MR, Clancey O, Episcopia K, Accordino D, Chalas E (2012) CyberKnife boost for patients with cervical cancer unable to undergo brachytherapy. Front Oncol 2, article 25
21.
Zurück zum Zitat Molla M, Escude L, Nouet P et al (2005) Fractionated stereotactic radiotherapy boost for gynecologic tumors: an alternative to brachytherapy? Int J Radiat Oncol Biol Phys 62(1):118–124CrossRef Molla M, Escude L, Nouet P et al (2005) Fractionated stereotactic radiotherapy boost for gynecologic tumors: an alternative to brachytherapy? Int J Radiat Oncol Biol Phys 62(1):118–124CrossRef
22.
Zurück zum Zitat Guckenberger M, Bachmann J, Wulf J, Mueller G, Krieger T, Baier K, Richter A, Wilbert J, Flentje M (2010) Stereotactic body radiotherapy for local boost irradiation in unfavourable locally recurrent gynaecological cancer. Radiother Oncol 94(1):53–59CrossRef Guckenberger M, Bachmann J, Wulf J, Mueller G, Krieger T, Baier K, Richter A, Wilbert J, Flentje M (2010) Stereotactic body radiotherapy for local boost irradiation in unfavourable locally recurrent gynaecological cancer. Radiother Oncol 94(1):53–59CrossRef
23.
Zurück zum Zitat Park HC, Shimizu S, Yonesaka A, Tsuchiya K, Ebina Y, Taguchi H, Katoh N, Kinoshita R, Ishikawa M, Sakuragi N, Shirato H (2010) High dose three-dimensional conformal boost using the real-time tumor tracking radiotherapy system in cervical cancer patients unable to receive intracavitary brachytherapy. Yonsei Med J 51:93–99CrossRef Park HC, Shimizu S, Yonesaka A, Tsuchiya K, Ebina Y, Taguchi H, Katoh N, Kinoshita R, Ishikawa M, Sakuragi N, Shirato H (2010) High dose three-dimensional conformal boost using the real-time tumor tracking radiotherapy system in cervical cancer patients unable to receive intracavitary brachytherapy. Yonsei Med J 51:93–99CrossRef
24.
Zurück zum Zitat Matsuura K, Tanimoto H, Fujita K, Hashimoto Y, Murakami Y, Kenjo M et al (2007) Early clinical outcomes of 3D-conformal radiotherapy using accelerated hyperfractionation without intracavitary brachytherapy for cervical cancer. Gynecol Oncol 104:11–14CrossRef Matsuura K, Tanimoto H, Fujita K, Hashimoto Y, Murakami Y, Kenjo M et al (2007) Early clinical outcomes of 3D-conformal radiotherapy using accelerated hyperfractionation without intracavitary brachytherapy for cervical cancer. Gynecol Oncol 104:11–14CrossRef
25.
Zurück zum Zitat Georg D et al (2008) Image-guided radiotherapy for cervix cancer: high-tech external beam therapy versus high-tech brachytherapy. Int J Radiat Oncol Biol Phys 71(4):1272–1278CrossRef Georg D et al (2008) Image-guided radiotherapy for cervix cancer: high-tech external beam therapy versus high-tech brachytherapy. Int J Radiat Oncol Biol Phys 71(4):1272–1278CrossRef
26.
Zurück zum Zitat Barraclough LH et al (2008) External beam boost for cancer of the cervix uteri when intracavitary therapy cannot be performed. Int J Radiat Oncol Biol Phys 71(3):772–778CrossRef Barraclough LH et al (2008) External beam boost for cancer of the cervix uteri when intracavitary therapy cannot be performed. Int J Radiat Oncol Biol Phys 71(3):772–778CrossRef
27.
Zurück zum Zitat Berggren D et al (1987) Postoperative confusion after anesthesia in elderly patients with femoral neck fractures. Anesth Analg 66(6):497–504CrossRef Berggren D et al (1987) Postoperative confusion after anesthesia in elderly patients with femoral neck fractures. Anesth Analg 66(6):497–504CrossRef
28.
Zurück zum Zitat Grosso G et al (2012) Major postoperative complications and survival for colon cancer elderly patients. BMC Surg 12(1):S20CrossRef Grosso G et al (2012) Major postoperative complications and survival for colon cancer elderly patients. BMC Surg 12(1):S20CrossRef
29.
Zurück zum Zitat Kirchheiner K et al (2014) Posttraumatic stress disorder after high-dose-rate brachytherapy for cervical cancer with 2 fractions in 1 application under spinal/epidural anesthesia: incidence and risk factors. Int J Radiat Oncol Biol Phys 89(2):260–267CrossRef Kirchheiner K et al (2014) Posttraumatic stress disorder after high-dose-rate brachytherapy for cervical cancer with 2 fractions in 1 application under spinal/epidural anesthesia: incidence and risk factors. Int J Radiat Oncol Biol Phys 89(2):260–267CrossRef
30.
Zurück zum Zitat Kirchheiner K et al (2015) Health related quality of life and patient reported symptoms before and during definitive radio (chemo) therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery—a mono-institutional prospective study. Gynecol Oncol 136(3):415–423CrossRef Kirchheiner K et al (2015) Health related quality of life and patient reported symptoms before and during definitive radio (chemo) therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery—a mono-institutional prospective study. Gynecol Oncol 136(3):415–423CrossRef
Metadaten
Titel
Definitive chemoradiation followed by stereotactic body radiotherapy boost for inoperable endometrial cancer
verfasst von
Shraddha M. Dalwadi
Constantine Mantz
Bui Tung
Nabila Waheed
Danny Tran
Mark Bonnen
Michelle Ludwig
Publikationsdatum
25.10.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Radiation Oncology / Ausgabe 3/2019
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-019-00403-0

Weitere Artikel der Ausgabe 3/2019

Journal of Radiation Oncology 3/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.